{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:32:32Z","timestamp":1785439952003,"version":"3.56.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jacc.2019.07.057","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T15:59:15Z","timestamp":1569254355000},"page":"1679-1681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-Life Insight Into Ibrutinib\u00a0Cardiovascular Events"],"prefix":"10.1016","volume":"74","author":[{"given":"Jutta","family":"Bergler-Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.07.057_bib1","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.057_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.057_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.07.057_bib4","first-page":"A14587","article-title":"Proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton\u2019s tyrosine kinase (BTK) used in cancer therapy (abstr)","volume":"132 Suppl 3","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.07.057_bib5","first-page":"847","article-title":"Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia","volume":"2","author":"Tomcsanyi","year":"2016","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2019.07.057_bib6","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2019.07.057_bib7","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2019.07.057_bib8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.07.057_bib9","first-page":"1491","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jacc.2019.07.057_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2019.07.057_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jacc.2019.07.057_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.07.057_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jacc.2019.07.057_bib14","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971936156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971936156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:16Z","timestamp":1760016256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971936156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":14,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S073510971936156X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.057","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-Life Insight Into Ibrutinib\u00a0Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.07.056","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}